Regeneron Pharmaceuticals' (REGN) Buy Rating Reaffirmed at Citigroup Inc.

Regeneron Pharmaceuticals' (REGN) Buy Rating Reaffirmed at Citigroup Inc.


's stock had its "buy" rating reaffirmed by research analysts at Citigroup Inc. in a report released on Friday. They currently have a $420.00 target price on the biopharmaceutical company's stock.



from Biotech News